Joint Comments by KEI, UACT, Social Security Watch and Health Gap on the proposed NIH Exclusive License in CAR Therapy to Lyell Immunopharma

On September 19, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Social Security Works (SSW), Health GAP, and Brook Baker submitted comments regarding the “Prospective Grant of an Exclusive Patent License: Development and Commercialization of CD19/CD22 Chimeric… Continue Reading

KEI, UACT, UAEM, and SSW Appeal NIH Grant of Exclusive Licenses on CAR Cancer Therapy to Gilead/Kite

On September 12, 2019, Knowledge Ecology International (KEI), Union for Affordable Cancer Treatment (UACT), Universities Allied for Essential Medicines (UAEM), Social Security Works (SSW), and Clare Love filed an appeal with the National Institutes of Health (NIH). The signatories appealed… Continue Reading

Senti Bio License for Development and Commercialization of Next Generation Chimeric Antigen Receptor (CAR) Therapies for the Treatment of FMS-Like tyrosine kinase 3 (FLT3) Expressing Cancers

On April 29, 2019, HealthGap, Knowledge Ecology International, Public Citizen, Social Security Works and the Union for Affordable Cancer Treatment filed comments on a proposed license on National Cancer Institute patented inventions to Senti Bio, for a next generation CAR… Continue Reading